CommercialCoverageMedium impact
Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance
Blue Cross & Blue Shield of Mississippi·MS · Urology, Oncology, Gastroenterology +2 more·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy establishes that all urinary biomarker tests for cancer screening, diagnosis, and surveillance are considered investigational and not covered, despite FDA approval of several tests. The policy affects both bladder cancer monitoring and colonic polyp screening tests.
Action Required
Immediately: Billing team must verify that urinary biomarker tests (BTA stat, BTA TRAK, NMP22, UroVysion, Bladder EpiCheck, and laboratory-developed tests) are not billed to this payer as they are considered investigational. Update billing system to flag these tests for denial prevention. Inform providers that alternative covered diagnostic methods should be used.